Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from.

Published byMelina Shavonne Robinson Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from."— Presentation transcript:

1 Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies  Boni E. Elewski, MD, Raza Aly, PhD, Sheryl L. Baldwin, RN, Remigio F. González Soto, MD, Phoebe Rich, MD, Max Weisfeld, DPM, Hector Wiltz, MD, CPI, Lee T. Zane, MD, Richard Pollak, DPM, MS  Journal of the American Academy of Dermatology  Volume 73, Issue 1, Pages (July 2015) DOI: /j.jaad Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Tavaborole chemical structure. Tavaborole is a novel, boron-based pharmaceutical approved for the treatment of toenail onychomycosis caused by Trichophyton rubrum and T mentagrophytes.1 Tavaborole inhibits leucyl-tRNA-synthetase, resulting in inhibition of fungal protein synthesis and termination of fungal cell growth.5 Journal of the American Academy of Dermatology  , 62-69DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Toenail onychomycosis. Patient disposition. ITT, Intent-to-treat. Journal of the American Academy of Dermatology  , 62-69DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Toenail onychomycosis. Illustrative cases of complete cure of the target great toenail (top) and almost clear nail with negative mycology (bottom) after treatment with tavaborole for 48 weeks. KOH, Positive potassium hydroxide wet mount. Journal of the American Academy of Dermatology  , 62-69DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Tavaborole efficacy in toenail onychomycosis. Change in efficacy end points over time from weeks 24 to 52. Each panel shows the percentage of patients achieving the end point at the indicated time point: complete cure (A); completely clear nail (CN) or almost CN (B); negative mycology (C); completely or almost CN plus negative mycology (D); and negative culture (E). ∗P ≤ .001 for tavaborole vs vehicle at week 52 for each of the end points assessed. Vertical lines indicate end of treatment at 48 weeks. Negative mycology was defined as negative potassium hydroxide wet mount and negative fungal culture. TGT, Target great toenail. Journal of the American Academy of Dermatology  , 62-69DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.
Understanding Treatment Goals for Patients With Onychomycosis

Understanding Treatment Goals for Patients With Onychomycosis
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata  Yong Hyun Jang, MD,

Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata  Yong Hyun Jang, MD,
A girl with a solitary red bulla

A girl with a solitary red bulla
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy of topical application of eosin for ulcerated hemangiomas

Efficacy of topical application of eosin for ulcerated hemangiomas
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
JAK inhibitors in dermatology: The promise of a new drug class

JAK inhibitors in dermatology: The promise of a new drug class
Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L
Comparison of the efficacy and safety of a picosecond alexandrite laser and a Q- switched alexandrite laser for the treatment of freckles in Chinese patients 

Comparison of the efficacy and safety of a picosecond alexandrite laser and a Q- switched alexandrite laser for the treatment of freckles in Chinese patients 
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Similar presentations

Ads by Google